Lenalidomide-Induced Second Cancer Risk Limited to Multiple Myeloma

Lenalidomide (Revlimid)-induced second primary malignancies appear to be limited to patients with multiple myeloma, according to a systematic review and meta-analysis.

While there was no significant increase in the risk of second primary malignancies associated with lenalidomide across all cancers (risk ratio [RR] 1.16, 95% CI 0.96-1.39), there was an increased risk associated with the immunomodulatory drug (IMiD) that was limited to myeloma trials (RR 1.42, 95% CI 1.09-1.84), reported Konstantinos Lontos, MD, of the University of Texas MD Anderson Cancer Cancer in Houston, and colleagues.

By comparison, no increased risk was detected in lenalidomide trials involving lymphoma or chronic lymphocytic leukemia (RR 0.90, 95% 0.76-1.08) and myelodysplastic syndrome (RR 0.96, 95% CI 0.23-3.97).

“Our findings suggest that physicians should not hesitate to use lenalidomide for indications other than multiple myeloma because of apprehension about the risk of [second primary malignancies],” the researchers wrote in The Lancet Haematology.

The systematic review involved 14,058 patients from 38 randomized trials that reported on patients treated with lenalidomide between 2004 and 2022.

Lontos and co-authors also evaluated the effect of lenalidomide on subtypes of second primary malignancies and found there was an increased risk of solid primary tumors in patients with multiple myeloma (RR 1.30, 95% CI 1.06-1.60), while the risk for a second hematologic malignancy was not significant (RR 1.26, 95% CI 0.93-1.70).

The authors suggested that the risk ratio of a second hematologic malignancy was likely affected by the FIRST trial due to its large size and the fact that it included patients in its non-lenalidomide group who used melphalan — a drug with known associations with increased risk of second primary hematologic malignancies — while the lenalidomide group did not include melphalan. In addition, Lontos and co-authors said, when the FIRST trial was excluded from the analysis, the risk ratio for a second primary hematologic malignancy did become statistically significant (RR 1.60, 95% CI 1.14-2.24).

Furthermore, the team noted, in the setting of multiple myeloma, use of lenalidomide increased both solid and hematologic second primary malignancies in both the no-transplantation (RR 1.25, 95% CI 1.04-1.51) and post-transplantation settings (RR 1.90, 95% 1.44-2.52).

The researchers also observed that there have been case reports of B-cell acute lymphocytic leukemia emerging from chronic lymphocytic leukemia and multiple myeloma after lenalidomide treatment. However, “continuous lenalidomide treatment has shown significant improvement in overall survival in patients with multiple myeloma, and the therapeutic benefit of lenalidomide remains greater than the impact of second primary malignancy,” Lontos and his colleagues emphasized.

Nevertheless, they said, in discussions with patients, clinicians should acknowledge the risk of lenalidomide-induced solid tumors and hematologic second primary cancers, and “apply it on an individual patient basis when making therapeutic decisions.”

In a commentary accompanying the study, Charlotte Pawlyn, PhD, and Sarah Bird, MD, both of the Royal Marsden Hospital and the Institute of Cancer Research in London, said the study raises several issues, including the question of the mechanism by which lenalidomide increases the risk of second primary cancers in multiple myeloma compared with other malignancies. Another question is whether this effect is limited to lenalidomide or also associated with other immunomodulatory drugs such as pomalidomide (Pomalyst), or with novel cereblon E3 ligase modulating drugs (CeLMODS) such as iberdomide and mezigdomide.

“Until we fully understand the mechanism(s) underlying a possible differential effect in [second primary malignancy] development between myeloma and other indications it remains prudent to continue monitoring patients taking IMiDs and CeLMODS” across all tumor types, including long-term follow-up in clinical trials, wrote Pawlyn and Bird.

  • author['full_name']

    Mike Bassett is a staff writer focusing on oncology and hematology. He is based in Massachusetts.

Disclosures

Lontos had no disclosures; several co-authors reported financial relationships with industry.

Pawlyn reported financial relationships with AbbVie, Amgen, Celgene/Bristol Myers Squibb, Janssen, Sanofi, and Takeda Oncology; Bird reported having no competing interests.

Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
Pan-Fried Chicken with Black Pepper Sauce thumbnail

Pan-Fried Chicken with Black Pepper Sauce

Pan-Fried Chicken with Black Pepper Sauce By: WellBeing Team Use PEARL RIVER BRIDGE Superior Light Soy Sauce as a dipping sauce with your favourite Asian snacks, or add it to stir-fries and marinades for an extra flavour infusion. It’s so versatile! Available at Coles and Woolworths. Ingredients 900g chicken legs, deboned Pinch salt Pinch sugar
Read More
Industry Payments Linked With Rheumatologists' Prescribing thumbnail

Industry Payments Linked With Rheumatologists’ Prescribing

UPDATED FEBRUARY 28, 2022 // Editor's note: This article, which originally attributed comments to Dr Karen Onel personally, has been updated to further emphasize that these comments were not on behalf of the committee that she leads. Payments to rheumatologists by pharmaceutical companies, whether through food and beverages or consulting fees, are linked with a…
Read More
Experience Stomach Pain After Consuming Vitamin C?  Turns out this is the cause thumbnail

Experience Stomach Pain After Consuming Vitamin C? Turns out this is the cause

SALAH satu cara untuk menjaga imunitas tubuh adalah dengan mengonsumsi kebutuhan vitamin. Beberapa vitamin yang dibutuhkan tubuh untuk menjaga imunitas adalah vitamin C dan Vitamin D. Selain menjaga imunitas, vitamin C juga bisa menjaga kulit kita agar tetap sehat. Vitamin C telah terbukti banyak berperan dalam menstimulasi sistem imunitas kita, disamping menjaga pola makan bergizi…
Read More
Weekly Check-up: Influenza increase in Southeast Brazil, cardiovascular health and more!  [podcast] thumbnail

Weekly Check-up: Influenza increase in Southeast Brazil, cardiovascular health and more! [podcast]

Avalie o nosso conteúdo: Houve um erro fazendo sua requisição, por favor tente novamente! Obrigado!Sua avaliação é fundamental para que a gente continue melhorando o Portal Pebmed O Portal PEBMED é destinado para médicos e demais profissionais de saúde. Nossos conteúdos informam panoramas recentes da medicina. Caso tenha interesse em divulgar seu currículo na internet,…
Read More
Lily James exudes modern elegance in polka dot co-ord thumbnail

Lily James exudes modern elegance in polka dot co-ord

London Fashion Week is drawing to a close, but Lily James is refusing to let her style game lose momentum, even for a second.The Mamma Mia! Here We Go Again star has been busy injecting the front row with a splash of her signature glamour – excellent news for fashion fans.Her latest appearance at the Vogue100
Read More
Reasons why you shouldn't take your kids to the mall even though it's allowed thumbnail

Reasons why you shouldn't take your kids to the mall even though it's allowed

PEMBATASAN Pergerakan Kegiatan Masyarakat (PPKM) periode 21 September – 4 Oktober 2021 telah memperbolehkan anak usia di bawah 12 tahun untuk memasuki pusat perbelajaan atau mal. Meski demikian orangtua diimbau untuk tidak membawa anaknya bepergian jika tidak terlalu mendesak untuk menghindari hal yang tidak diinginkan. Sebagaimana diketahui tingkat risiko Covid-19 pada anak memang tidak terlalu…
Read More
Index Of News
Consider making some contribution to keep us going. We are donation based team who works to bring the best content to the readers. Every donation matters.
Donate Now

Subscription Form

Liking our Index Of News so far? Would you like to subscribe to receive news updates daily?

Total
0
Share